THM is used in combination with conventional treatments to enhance efficacy and reduce side effects.[10] It has been reported that THM is effective as an adjuvant therapy in patients with NSCLC.[11] In particular, THM combined with EGFR-TKI increases progression-free survival (PFS) and overall survival (OS), improves quality of life, decreases side effects, and delays acquired resistance in patients with advanced NSCLC.[11–14]. Here, EGFR is linked to non-small cell lung carcinoma.